«Machine learning might identify patients earlier, predict their outcomes better, and assign them more efficiently to appropriate clinical trials.» Read the full article highlighting machine learning in relation to ALS, on the Nature International Journal of Science, here.
Communicate the “Who, What, and Why,” at All Stages of Your Journey: 5 Tips With Harvey Gaffen
“Open, honest communication has helped us find and secure resources, publicize the compelling stories of the people we serve, showcase our accomplishments, and attract new donors.” «I had the pleasure of interviewing Harvey Gaffen, president emeritus of the Les Turner ALS …
Column: Amid the ugliness of ALS lies the beauty of love
December 29, 2017 – Everything is an opportunity for something. That’s what Holly Kahan told a group of women at a recent networking meeting I attended. That seemed like a pretty reasonable statement, which can be applicable to many difficult …
2018 Grants to Center
Your advocacy for advancements towards a cure allow us to continue innovative research in 2018. The Foundation will award over $1.1 million to the Center in 2018. This gift will fund six new research grants and continued support of the …
2017 Year in Review
As 2017 comes to a close, see what you accomplished: You supported research that led to Radicava, the first FDA approved drug in 22 years.You raised over $2 million at events that inspired the ALS community. You educated others and …
Meet the New Center Director: Q&A
Join us in welcoming Robert Kalb, MD, the inaugural Director of the Les Turner ALS Research and Patient Center at Northwestern Medicine and Chief of Neuromuscular Medicine in the Ken & Ruth Davee Department of Neurology. Dr. Kalb has spent …
C.H.A.R.M Through the Holidays
For most people, the holidays are a time of joy and good cheer. But when living with ALS, or providing care for someone who does, holiday activities have the potential to add stress to an otherwise happy season. Over the years, …
Cytokinetics Announces Negative Results from VITALITY-ALS
Cytokinetics announced the endpoints for the clinical trial of tirasemtiv (VITALITY-ALS) had not been met and that further development of the drug was being suspended. We share Cytokinetics, and your, disappointment in this announcement and are grateful for Cytokinetics continued …
2018 Chicago Marathon Refer a Friend Contest
Know someone who loves to run? You can win $200 for yourself and $100 for your friend by asking them to run with Team Race for ALS in the 2018 Bank of America Chicago Marathon! Take these easy steps to …
Run with Team Race for ALS: 2018 Chicago Marathon
Now is your chance to accomplish something HISTORIC for yourself and the entire ALS community: Run with Team Race for ALS in the 2018 Bank of America Chicago Marathon. Registration closes November 29. If you’ve ran the Chicago Marathon with …
